

## Agenda

### **PARP Inhibitors in Ovarian Cancer: Clinical Efficacy and Ongoing Studies**

***Robert L. Coleman, MD, FACOG, FACS, Program Chair***

Executive Director, Cancer Network Research

MD Anderson Cancer Center

Houston, TX

#### **Interactive Panel of Expert Insights**

##### **Topic 1. Which agent(s) and how to sequence in the maintenance setting?**

***Lead Discussant:***

***Ursula A. Matulonis, MD***

Brock-Wilson Family Chair in Gynecologic Oncology Research

Director, Gynecologic Oncology

Susan F. Smith Center for Women's Cancer

Dana-Farber Cancer Institute

Professor of Medicine

Harvard Medical School

Boston, MA

##### **Topic 2. How to minimize potential toxicities and improve tolerability?**

***Lead Discussant:***

***Kathleen N. Moore, MD***

Jim and Christy Everest Endowed Chair in Cancer Research

Director, Oklahoma TSET Phase I Program

Stephenson Cancer Center

Associate Professor, Section of Gynecologic Oncology

Director Gynecologic Oncology Fellowship

Department of Obstetrics and Gynecology

University of Oklahoma Health Sciences Center

Oklahoma City, OK

##### **Topic 3. Can PARP inhibitor resistance be predicted? What is the clinical impact and potential strategies used to overcome mechanisms of resistance?**

***Lead Discussant:***

***Gottfried E. Konecny, MD***

Professor of Medicine

UCLA, Department of Medicine, Medical Gynecologic Oncology

Los Angeles, CA

##### **Topic 4. Biomarkers to Direct PARP Inhibitor Therapy**

***Lead Discussant:***

***Angeles Alvarez Secord, MD, MHSc***

Professor of Obstetrics & Gynecology

Duke University Medical Center

Durham, NC

